TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. §371

OCT 2 3 1999

ATTORNEY DOCKET NUMBER 263/PPIR2548US

2 3 OCT 1998

U.S. APPLICATION NO.

(if known, see 37 CFR 1.5) 09/155,076

International Filing Date
March 21, 1997

Priority Date Claimed March 22, 1996

PCT/GB97/00796 Title of Invention

PEPTIDE FROM SOLUBLE FORM OF ACETYLCHOLINESTERASE, ACTIVE AS A CALCIUM CHANNEL MODULATOR

Applicant(s) For DO/EO/US

International Application No.

Susan Adele GREENFIELD and David John Talbutt VAUX

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

- 1. [] This is a FIRST submission of items concerning a filing under 35 U.S.C. §371.
- 2. [X] This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. §371.
- 3. [] This express request to begin national examination procedures (35 U.S.C. §371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. §371(b) and PCT Articles 22 and 39(1).
- 4. [] A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
- 5. [] A copy of the International Application as filed (35 U.S.C. §371(c)(2))
 - a. [] is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. [] has been transmitted by the International Bureau.
 - c. [] is not required, as the application was filed in the United States Receiving Office (RO/US)
- 6. [] A translation of the International Application into English (35 U.S.C. §371(c)(2)).
- 7. [] Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. §371(c)(3)).
 - a. [] are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. [] have been transmitted by the International Bureau.
 - c. [] have not been made; however, the time limit for making such amendments has NOT expired.
 - d. [] have not been made and will not be made.
- 8. [X] An executed oath or declaration of the inventor(s) (35 U.S.C. §371(c)(4)). ATTACHMENT A
- 9. [] A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. §371(c)(5)).

Items 10. to 13. below concern other document(s) or information included:

- 10. [] An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
- 11. [X] An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. ATTACHMENT B
- 12. [] A FIRST preliminary amendment.
 - [] A SECOND or SUBSEQUENT preliminary amendment.

Other items or information: 00000093 09155076

.0/27/199 1 FC:254

65.00 np

COPY, BUMBLE FOR USPIDA

THE COMMISSION IN AUTHORIZED TO CHARGE ANY DEFICIENCY IN THE FEE FOR THIS PAPER TO DEPOSIT ACCC.

ч

¢

U.S. APPLICATION NO. (if known, see 37 CFR 1.5) 09/155,076		INTERNATIONAL APPLICATION NO. PCT/GB97/00796		ATTORNEY'S DOCKET NO. 263/PPIR2548US	
14. [X] The following fees are submitted				CALCULATIONS	PTO USE ONLY
BASIC NATIONAL FE	E (37 CFR 1.492	(a)(1)-(5)):	,		
[] Search Report has been prepared by the EPO or JPO					
[] Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO\$1,070.00					
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$	
Surcharge of \$130.00 for furnishing the oath or declaration later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$65.00	
Claims	Number Filed	Number Extra	Rate	<u>.</u>	
Total Claims	-20 =		X \$22.00	\$	
Independent Claims	- 3 =		X \$82.00	\$	
Multiple dependent claim(s) (if app	plicable)		+ \$270.00	\$	
TOTAI	JOF ABOVE	CALCULATIONS =	:	\$65.00	
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28)				s	
SUBTOTAL =				\$65.00	
Processing fee of \$130.00 for furnishing the English translation later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
	TOTAL	NATIONAL FEE =	:	\$65.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +				\$40.00	
	TOTAL F	FEES ENCLOSED =		\$105.00	
			į	Amount to be refunded	\$
				Amount to be charged	s
a. [X] A check in the amount of \$105.00 to cover the above fees is enclosed. A duplicate copy of this form is enclosed.					
b. [] Please charge my Deposit Account No. 23-0975 in the amount of \$ to cover the above fees. A duplicate copy of this sheet is enclosed.					
c. [] The Commissioner is hereby autloverpayment to Deposit Account	norized to charge any addit nt No. <u>23-0975</u> . A duplic	itional fees which may be required, or attention at the copy of this form is enclosed.	credit any		
NOTE: Where an appropria (b)) must be filed and grante	ite time limit under id to restore the app	37 CFR 1.494 or 1.495 has plication to pending status.	; not been met, a p	etition to revive (37 C	FR 1.137(a) or
SEND ALL CORRESPONDENCE TO: WENDEROTH, LIND & PONACK, L.L.P. 2033 K St., N.W., Ste. 800 Warren M. Cheek, Jr. NAME 33,367 REGISTRATION NUMBER					

[CHECK NO. 30315] [98-0967*/WMC/263]

October 23, 1998

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Susan Adele GREENFIELD et al.

: ATTN: APPLICATION BRANCH

Serial No. NEW

Attorney Docket No.

263/PPIR2548US

Filed September 21, 1998

PEPTIDE FROM SOLUBLE FORM OF ACETYLCHOLINESTERASE, ACTIVE AS A CALCIUM CHANNEL MODULATOR

PRI COMMISSIONER IS AUTHORIESD TO CULTURAL DEFICIESCY IN THE MAZI FOR THIS PAPER TO DEPOSIT

ACCOUNT NO. 23-0975.

COVER LETTER FOR APPLICATION FILED WITHOUT ORIGINAL EXECUTED DECLARATION

Assistant Commissioner for Patents,

Washington, D.C. 20231

The above-identified application has been submitted without an sir: original executed oath or declaration pursuant to 37 CFR 1.41(c).

It is respectfully requested that this application be assigned a serial number and awarded a filing date pursuant to 37 CFR 1.53.

A duly executed original oath or declaration pursuant to 37 CFR 1.63 will be submitted after notification by the U.S. Patent and Trademark Office pursuant to 37 CFR 1.53(d).

An unexecuted copy of the Declaration and Power of Attorney, containing the required inventorship information, is attached herewith. It is respectfully requested that all communications be directed to the firm indicated on the attached Declaration and Power of Attorney, namely:

WENDEROTH, LIND & PONACK, L.L.P. 2033 K Street, N.W., Suite 800 Washington, D.C. 20006 The required \$776.00 U.S. Patent and Trademark Office filing fee is attached herewith. Respectfully submitted, Susan Adele GREENFIELD et al. By: Warren M. Cheek Jr.
Registration No. 33,367 Attorney for Applicants WMC/dlk Washington, D.C. 20006 Telephone No. (202) 721-8200 September 21, 1998 - 2 -

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

: ATTN: BOX MISSING PART Susan Adele GREENFIELD et al.

Serial No. 09/155,076

Attorney Docket No. Filed September 21, 1998 263/PPIR2548US

PEPTIDE FROM SOLUBLE FORM OF ACETYLCHOLINESTERASE, ACTIVE AS A CALCIUM CHANNEL MODULATOR

SUBMISSION OF EXECUTED DECLARATION

Assistant Commissioner for Patents, Washington, D.C. 20231

Enclosed herewith is an executed Declaration for the sir: above-identified application which was originally filed without an executed Declaration.

The Declaration identifies the application by the Title, name of the inventors, and filing date of the application.

Accordingly, it is submitted that the present application now complies with the requirements of 37 CFR 1.53(d).

Enclosed herewith is the \$65.00 surcharge required by 37 CFR 1.16(e). Also enclosed is the required copy of the Notice to file Missing Parts of Application.

Early issuance of a filing receipt is therefore requested.

Respectfully submitted,

Susan Adele GREENFIELD et al.

Warren M. Cheek, Jr. Registration No. 33,367 Attorney for Applicants

WMC/dlk Washington, D.C. Telephone No. (202) 721-8200 October 23, 1998